| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Aug 2025 | 24 Jul 2025 |
| Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 inter alia to consider and approve Standalone and Consolidated Results for Q1FY26 Standalone and Consolidated Unaudited Financial Results Financial Results (As per BSE Announcement Dated on 11.08.2025) | ||
| Board Meeting | 29 May 2025 | 14 May 2025 |
| Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve Standalone & Consolidated Audited Financial Results for the 4th Quarter and FY25 and recommendation of final dividend for FY 24-25 Board Meeting Outcome for Standalone And Consolidated Audited Financial Results For Q4FY25 Standalone and Consolidated Audited Financial Results for Q4FY25 Amendment to Memorandum of Association (As Per BSE Announcement Dated on: 29/05/2025) | ||
| Board Meeting | 28 Mar 2025 | 28 Mar 2025 |
| Outcome of Board Meeting - 28.03.2025 | ||
| Board Meeting | 13 Feb 2025 | 27 Jan 2025 |
| IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results for Q3 and nine months ended 31st December 2024 Standalone and Consolidated Q3FY25 Results & Press Release (As Per BSE Announcement Dated on: 13/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 24 Oct 2024 |
| IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Standalone and Consolidated Financial Results for 2nd quarter and half year ended 30th September 2024 and Declaration of Interim Dividend Board declares Interim Dividend of Rs. 2/- per share of Re. 1/- each (200%) (As per BSE Announcement Dated on 14/11/2024) | ||
This consolidation aims to streamline all of Ipca Group's US generics formulations under a single entity, enhancing operational efficiency.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
